Trial Profile
A Prospective Randomized and Phase II Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Mesna
- Indications Malignant melanoma
- Focus Therapeutic Use
- 04 Nov 2023 Status changed from recruiting to suspended.
- 11 Feb 2022 Status changed from active, no longer recruiting to recruiting.
- 10 Feb 2022 Status changed from suspended to active, no longer recruiting.